Tag: Zetagen Therapeutics

Zetagen Therapeutics Closes Oversubscribed Series B1 Round on Strength of Promising Phase 2a Data and Compelling Pipeline

Zetagen Therapeutics Closes Oversubscribed Series B1 Round on Strength of Promising Phase 2a Data and Compelling Pipeline

The funding round closed with strong demand from private investors—led by JSTAR Capital Investments—demonstrating deep confidence in our clinical efficacy. SYRACUSE, N.Y.–(BUSINESS WIRE)–Zetagen Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments…

Read More Read More

Zetagen Therapeutics has filed a notice of an exempt offering of securities to raise $6,173,828.00 in New Equity Investment.

Zetagen Therapeutics has filed a notice of an exempt offering of securities to raise $6,173,828.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Zetagen Therapeutics is raising up to $6,173,828.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold…

Read More Read More

Zetagen Therapeutics has filed a notice of an exempt offering of securities to raise $15,000,000.00 in New Equity Investment.

Zetagen Therapeutics has filed a notice of an exempt offering of securities to raise $15,000,000.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Zetagen Therapeutics is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Tischler played a key role in…

Read More Read More